Crossmark

Expansion of Molecular and Clinical Aspects of EPS8L2 (DFNB106)-Associated Hearing Loss Emphasizes a Potential Therapeutic Window

Crossref DOI link: https://doi.org/10.1007/s12035-025-05615-9

Published Online: 2026-01-10

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Owrang, Daniel https://orcid.org/0000-0002-3055-3613
Rad, Aboulfazl https://orcid.org/0000-0001-8627-8828
Alerasool, Masoome

Kolb, Susanne M.

Lin, Sheng-Jia https://orcid.org/0000-0002-7559-6529
Doll, Julia https://orcid.org/0000-0002-0037-9079
Alidadiani, Neda

Ghaderi, Shahrooz https://orcid.org/0000-0002-0124-3026
Hofrichter, Michaela A. H.

Maroofian, Reza https://orcid.org/0000-0001-6763-1542
Varshney, Gaurav K. https://orcid.org/0000-0002-0429-1904
Mojarrad, Majid https://orcid.org/0000-0001-8742-2844
Bartsch, Oliver https://orcid.org/0000-0001-6329-696X
Haaf, Thomas https://orcid.org/0000-0002-0737-0763
Vona, Barbara https://orcid.org/0000-0002-6719-3447
Funding

Funding for this research was provided by:

Herzzentrum Göttingen
License Information

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2026-01-10
More Information

Article History

Received: 14 August 2025

Accepted: 8 December 2025

First Online: 10 January 2026

Declarations

:

: This study was approved by the Medical Faculty of the University of Würzburg, Germany (approval number 46/15), and the Ethics Committee of Mashhad University of Medical Sciences (IR.MUMS.MEDICAL.REC.1402.090).

: Written informed consent from the parents or legal guardians of the patients/participants was obtained for study participation.

: Written informed consent from the parents or legal guardians of the patients/participants was obtained for publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below